Gibbs Wealth Management’s Adaptive Biotechnologies ADPT Stock Holding History

Gibbs Wealth Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$383K	Buy	+27,592	New	+$440K	0.05%	349

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Gibbs Wealth Management's ADPT Position: Q1 2026 in Review

Gibbs Wealth Management opened a new position in Adaptive Biotechnologies (ADPT) in Q1 2026: 27,592 shares worth $383K. The stake represents 0.05% of the portfolio and ranks #349 among its holdings.

298 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

Gibbs Wealth Management held 27,592 shares of Adaptive Biotechnologies worth $383K as of Q1 2026.
Adaptive Biotechnologies was a new Gibbs Wealth Management position in Q1 2026.
Adaptive Biotechnologies made up 0.05% of Gibbs Wealth Management's portfolio in Q1 2026, its #349 holding.
298 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Gibbs Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.